NovaBay®
Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company
focusing on the development and commercialization of topical
non-antibiotic anti-infective products, announces the rebranding
of its i-Lid
Cleanser with Neutrox™ as Avenova™
with Neutrox. This name change, effective immediately, helps NovaBay
to differentiate prescription Avenova from other products
marketed as eye cleaners, in particular over-the-counter (OTC) products
not intended for continuous daily use.
Avenova™ with Neutrox (Photo: Business Wire)
Avenova is the only eye care product to contain Neutrox,
NovaBay’s pure hypochlorous acid (HOCl), which is a naturally occurring
substance produced by white blood cells to fight microbial invaders.
Laboratory tests show it has potent antimicrobial activity in solution
yet is non-toxic to mammalian cells; it also neutralizes bacterial
toxins.
“Avenova is uniquely suited for daily use by the millions of
Americans who suffer from chronic eye conditions like blepharitis and
dry eye. Yet far too many ophthalmologists and optometrists have
confused prescription Avenova with OTC surfactant lid cleaners,”
explained Glenn Moro, NovaBay’s Vice President for Sales and Marketing.
“While those OTC products are effective for their intended uses, none is
designed for continuous daily eyelid hygiene.”
“Avenova is a real breakthrough in eye care,” said Terrence
P. O'Brien, M.D., Director of the Refractive Surgery Service, Bascom
Palmer Eye Institute at Palm Beach Gardens. “This product fills a
medical need not being met by current products.”
According to Art Epstein, O.D., Director of the Dry Eye & Ocular Surface
Disease Center and Director of Clinical Research at Phoenix
Eye Care, Avenova makes possible a new paradigm for eye care.
“Historically eye care specialists have brought relief to patients who
present with conditions like blepharitis, where Staphylococci
bacteria grow on eyelids and cause swelling, redness, inflammation,
irritation and a crusty build-up. While Avenova is effective as
part of the regimen for managing those conditions, regular use of Avenova
may prevent such problems before they occur, much as daily flossing
helps to prevent dental problems,” he said.
“Changing the name of our ophthalmic anti-infective cleanser from i-Lid
Cleanser to Avenova will reinforce our marketing message that Avenova
brings a powerful new prescription tool to eye care,” said Ron Najafi,
Ph.D., Chairman and CEO of NovaBay. “Once eye care professionals
prescribe Avenova, we believe they will quickly experience the
improvement it has on the lives of their patients.”
Avenova was cleared by the U.S. Food and Drug Administration as a
prescription medical device through the 510(k) process (see below for
Indications for Use statement). As previously announced, NovaBay signed
a distribution
agreement with McKesson Corporation, the largest pharmaceutical
distributor in North America, making Avenova available to the
45,000 pharmacies it services across the U.S. In addition, Avenova
is now available to the members of the Vision
Source Independent Optometry Network. Vision Source is the largest
independent optometry network in the country, representing 2,800
independent optometrist offices.
For NovaBay Avenova purchasing information, please contact:
Email
us
Call us: 1-800-890-0329
www.avenova.com
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the
development and commercialization of its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories:
Aganocide® compounds, led by auriclosene, and its FDA-cleared Neutrox™
Family of Products: NeutroPhase® for wound care, Advanced i-Lid™
Cleanser for the eye care market and CelleRx™ for the dermatology market.
*Avenova Skin and Wound Cleanser is intended for use under the
supervision of healthcare professionals for cleansing and removal of
foreign material, including microorganisms and debris from wounds, and
for moistening absorbent wound dressings and cleaning minor cuts, minor
burns, superficial abrasions and minor irritations of the skin. It is
also intended for moistening and debriding acute and chronic dermal
lesions, such as Stage I to IV pressure ulcers, stasis ulcers, leg
ulcers, diabetic foot ulcers, post surgical wounds, first and second
degree burns, grafted and donor sites.
Forward-looking Statements
This release contains forward-looking statements and opinions
regarding the commercial potential of Avenova, which are based upon
management's current expectations, assumptions, estimates, projections
and beliefs. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those expressed
in or implied by the forward-looking statements. Factors that might
cause or contribute to such differences include, but are not limited to,
risks and uncertainties relating to the actual market acceptance of
Avenova, the clinical effectiveness of Avenova, and the possibility that
customers will not perceive the benefits of Avenova to be the same as
NovaBay believes. Other risks relating to NovaBay and its products,
including risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release, are
detailed in NovaBay's latest Form 10-K and Form 10-Qs as filed with the
Securities and Exchange Commission, especially under the heading "Risk
Factors." The forward-looking statements in this release speak only as
of this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required by
law.
Stay informed on NovaBay's progress:
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit
NovaBay's
Website
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150105005323/en/
Copyright Business Wire 2015